ctDNA Monitoring in Patients With HCC and mCRC

Launched by MEDICAL UNIVERSITY OF WARSAW · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new blood test called ctDNA (circulating tumor DNA) to see if it can help monitor patients with liver cancer (hepatocellular carcinoma, or HCC) and colorectal cancer that has spread to the liver. The goal is to find out if this test can detect cancer recurrence early, assess how the cancer is progressing, and help doctors adjust treatments to improve patient outcomes. By analyzing a small blood sample, researchers hope to track changes in the levels of ctDNA over time, which could give important clues about the patient's health.

To participate in this trial, you must be between 18 and 75 years old and have specific types of cancer, including colorectal cancer that has spread to the liver or liver cancer that can be surgically removed. You will provide blood samples before, one month after, and six months after surgery, and the study will last for 18 months. Participants in the study will receive regular follow-ups and care based on the best practices for their condition. It's important to note that this trial is currently recruiting participants, and those interested should discuss their eligibility with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age 18-75 years of both sexes;
• • patients with synchronous or metachronous metastases of colorectal cancer limited to the liver after complete removal of the primary lesion from the intestine qualified for liver resection or transplantation;
• • or patients with resectable or unresectable HCC scheduled for liver resection or transplantation
• • no history of other cancers;
• • negative virological status in the case of mCRC;
• • In the case of mCRC - patient after any type of liver surgery (staged, ALPPS, multi-site resection)
• • Patient with or without neoadjuvant chemotherapy compatible with established adjuvant therapy
• Exclusion Criteria:
• • age under 18 and over 75;
• • pregnancy
• • patients with extrahepatic metastases visible in imaging studies;
• • metabolic and autoimmune diseases or chronic immunosuppressive treatment other than in the group of patients after liver transplantation due to HCC;
• • positive virological status, excluding the group of patients with HCC;
• • history of other cancer;
• • Chronic steroid therapy and diagnosed active autoimmune diseases
• • Patient after radiotherapy
• • Patient participating in other clinical trials of oncological and non-oncological drugs
• • Patients legally incapacitated